Abstract:Gut dysbiosis has been associated with inflammatory bowel disease (IBD), one of the most common gastrointestinal diseases. The microbial communities play essential roles in host physiology, with profound effects on immune homeostasis, directly or via their metabolites and/or components. There are increasing clinical trials applying fecal microbiota transplantation (FMT) with Crohn's disease (CD) and ulcerative colitis (UC). The restoration of dysbiotic gut microbiome is considered as one of the mechanisms of FMT therapy. In this work, latest advances in the alterations in gut microbiome and metabolome features in IBD patients and experimental mechanistic understanding on their contribution to the immune dysfunction were reviewed. Then, the therapeutic outcomes of FMT on IBD were summarized based on clinical remission, endoscopic remission and histological remission of 27 clinical trials retrieved from PubMed which have been registered on ClinicalTrials.gov with the results been published in the past 10 years. Although FMT is established as an effective therapy for both subtypes of IBD, the promising outcomes are not always achieved. Among the 27 studies, only 11 studies performed gut microbiome profiling, 5 reported immune response alterations and 3 carried out metabolome analysis. Generally, FMT partially restored typical changes in IBD, resulted in increased α-diversity and species richness in responders and similar but less pronounced shifts of patient microbial and metabolomics profiles toward donor profiles. Measurements of immune responses to FMT mainly focused on T cells and revealed divergent effects on pro-/anti-inflammatory functions. The very limited information and the extremely confounding factors in the designs of the FMT trials significantly hindered a reasonable conclusion on the mechanistic involvement of gut microbiota and metabolites in clinical outcomes and an analysis of the inconsistencies.

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Fecal transplantation for treatment of inflammatory bowel disease.

Fecal Microbiota Transplantation in Inflammatory Bowel Disease

Microbiota Therapy in Inflammatory Bowel Disease

Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation

The Role of Fecal Microbiota Transplantation in IBD

Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease

Current and future microbiome-based therapies in inflammatory bowel disease

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it

Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease

Dissecting mechanisms of fecal microbiota transplantation efficacy in disease

Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease

Probiotics, Prebiotics, Fecal Microbiota Transplantation, and Dietary Patterns in Inflammatory Bowel Disease

The emerging role of the gut microbiota and its application in inflammatory bowel disease

Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns

The role of the fecal microbiota in inflammatory bowel disease

Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges

Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in Children

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

The Role of Fecal Microbiota Transplantation in the Induction of Remission in Ulcerative Colitis